Found 126 clinical trials
ANBL00B1: Biomarkers in Tumor Tissue Samples from Patients with Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
ANBL00B1: Biomarkers in Tumor Tissue Samples from Patients with Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
- 104 views
- 08 Nov, 2020
- 1 location
ANBL12P1: Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
ANBL12P1: Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
- 120 views
- 08 Nov, 2020
- 1 location
ANBL0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
ANBL0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
- 600 views
- 08 Nov, 2020
- 1 location
ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children With Refractory, Relapsed or Progressive Neuroblastoma
, Relapsed or Progressive Neuroblastoma
- 304 views
- 08 Nov, 2020
- 1 location
ACNS0821:Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
ACNS0821:Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
- 112 views
- 08 Nov, 2020
- 1 location
European Low and Intermediate Risk Neuroblastoma Protocol
The European study, LINES 2009 (Low and Intermediate Risk Neuroblastoma European Study), groups together in a single protocol the treatment of all patients with "non high risk" neuroblastoma (NB
- 125 views
- 23 Jan, 2021
- 82 locations
Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours
A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.
- 41 views
- 09 Apr, 2023
- 22 locations
Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood. (CSIIT-Q36)
Neuroblastoma is a malignant tumor that develops in infants and kids. Dysregulation of histone acetylation is associated with a series of malignant tumors. Neuroblastoma is caused by defective
- 0 views
- 01 Jul, 2022
- 1 location
Etoposide and Cisplatin in Treating Young Patients With Previously Untreated High-Risk Neuroblastoma Undergoing High-Dose Chemotherapy Stem Cell Transplant and Isotretinoin
the side effects and how well giving etoposide together with cisplatin works in treating young patients with previously untreated high-risk neuroblastoma undergoing high-dose chemotherapy
- 24 views
- 07 Nov, 2020
- 1 location
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction
- 0 views
- 18 Oct, 2022
- 1 location